Clinical Trial Update: Entecavir to TAF Switch [Phase 3]

View source ↗

Summary

Clinical trial update on switching from entecavir to tenofovir alafenamide (TAF) in Hepatitis B patients (Phase 3, active not recruiting).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis B

Drugs mentioned

• ENTECAVIR (ENTECAVIR)
• Tenofovir alafenamide (tenofovir alafenamide)

Snippet

Sponsor: Thomas Jefferson University | Conditions: Hepatitis B | Phase 3 | Status: ACTIVE_NOT_RECRUITING